Sean "Diddy" Combs is again offering his Miami mansion as collateral for $50M bail package, arguing that at worst, he's just ...

The FDA’s complete response letter cited concerns that the Phase I/II IGNYTE (NCT03767348) trial in advanced melanoma was not ...

FDA issues a complete response letter for glofitamab's second-line DLBCL indication, highlighting ongoing scrutiny in ...

In the second quarter of 2025, fund assets appreciated by 6.7%. For the three-year period, the fund is up 46.6% 1 compared to ...

The CRL was given because the FDA did not consider the phase 1/2 IGNYTE trial to be an adequate and well-controlled clinical ...

Swiss pharma giant Roche has won approval from the UK’s Medicines and Healthcare Regulatory Agency (MHRA) for its combination treatment of Columvi (glofitamab) alongside gemcitabine and oxaliplatin ...

Union Pacific Corp. agreed to acquire Norfolk Southern Corp. in a cash-and-stock transaction valued at $85 billion, forming a ...

Though atomic nuclei are often depicted as static clusters of protons and neutrons (nucleons), the particles are actually ...

Addverb, a global leader in robotics and warehouse automation solutions, announces a new partnership with S. Abraham and Sons ...

A key safe means your property stays secure while those you authorise can come and go. Our shopping team gives their honest ...

Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the U.S. Food and Drug Administration ...

The FDA determined the data from STARGLO did not provide sufficient evidence to support approving glofitamab-gxbm (Columvi) in combination with gemcitabine and oxaliplatin to treat relapsed/refractory ...